LNTH — Biotech & Pharma Setup
Lantheus is posting 76.5% EPS growth year-over-year, well above the 40% elite threshold, though revenue growth lags at 1.2%. The technical setup is clean: Stage 2 confirmed with all eight trend criteria passing, VCP tight, and volume drying up perfectly to signal a compressed base ready to move. Entry now is structurally sound. Price sits 2.1% above MA20 in the cheat entry window before a formal breakout. Risk to the calculated stop at $100.83 is 7.0%—moderate and defined. No earnings within 10 trading days removes that variable. Confirmation comes if price holds above $102.37 (cheat entry support) and begins trending toward the 52W high at $110.94, just 2.3% away. The trade breaks if price closes below the stop, signaling the base failed to hold. Best entry window is 10:00–10:30 AM after opening volatility settles—confirm price is holding near MA20 before entering.
Close below $100.83
No. The original thesis claimed price would hold above the $102.37 cheat entry support level and begin trending toward the 52-week high at $110.94, with breakage only upon a close below the $100.83 stop. Instead, price broke the stop on the very next day, closing at $100.83 and triggering the auto-exit. The thesis was invalidated within a single trading session—the base did not hold, and no uptrend initiated.
The scanner correctly identified that Stage 2 was confirmed, all eight trend criteria passed, and the volume compression pattern was genuine and tight. The risk calculation was accurate; the stop distance of 7.0% and the defined risk structure itself were sound. The entry price of $108.4 was positioned logically within the cheat entry window, and the tape behavior in the first few hours appeared to support the technical setup. The scanner's B-grade assessment of overall quality was appropriate given the strong EPS growth and leadership rank; the entry signal itself was valid in isolation.
The thesis failed to anticipate or hedge against rapid mean reversion back toward the MA20 and through the support zone. Although the technical setup appeared clean on the scanner, the setup lacked sufficient confirmation of buyer commitment at the entry level; price moved 2.1% above MA20 on the cheat entry but did not sustain momentum or gather volume support to validate the breakout thesis. The one-day hold reveals that the compressed base, while real, was not yet ready to move higher—or buyer interest evaporated immediately. No earnings catalyst risk was identified, but no catalyst of any kind was recorded to justify entry into a thinly-moving biotech name at that precise moment.
| Rubric Section | Signal | Assessment |
|---|---|---|
Market Regime |
Partial | Caution regime was flagged at entry, yet the thesis proceeded with early entry; Caution warranted more conservatism or confirmation before cheat entry. |
Leadership Quality |
Accurate | RS rank of 86 and Tier 1 status were correctly identified and held throughout the hold period. |
Fundamental Quality |
Partial | EPS growth was elite, but the 1.2% revenue growth is a red flag for sustainability; the Quality Score of 70/100 reflected this weakness but did not override entry conviction. |
Setup Structure |
Partial | Stage 2 and all trend criteria passed, and the VCP/volume pattern was genuine, but the setup lacked the confirmation candle or volume surge that would have indicated readiness to move. |
Lifecycle Phase |
Accurate | Stage 2 was correctly assessed; however, the position within that stage (early base compression vs. late pre-breakout) was not granular enough to prevent premature entry. |
Capital Protection |
Accurate | The stop was logical and the risk-to-reward framework was sound; the stop executed as designed at -1R. |
Character Assessment |
Missed | No notes on character or tape behavior were recorded; intraday tape reading might have revealed lack of conviction from buyers at the $108+ level. |
Consider adding a confirmation gate within the entry rubric that requires at least one full trading session of price holding and stabilizing above the key support level (in this case, $102.37) before a cheat entry is marked valid, particularly in lower-volume sectors like biotech. Cheat entries on compression setups should earn a pass only if the prior day's close or first hour of the current session demonstrates that support is holding with flat-to-rising volume; a single hour of entry validity is insufficient for conviction.
The Caution regime at entry suggests the broader market was already in a risk-off posture on July 26, 2026. Biotech and pharma stocks are often among the first to roll over in Caution regimes as sector rotation favors defensive names. No data on sector-specific behavior during the single-day hold is available, but the rapid drop to the stop on July 27 is consistent with overnight or early-session sector weakness that caught the position off-guard. The speed of the exit suggests institutional selling or short covering, not a slow bleed.